Boehringer Ingelheim Reports Results from the P-II Study of Survodutide for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Shots:
- The P-II study investigates survodutide (SC, 2.4mg, 4.8mg & 6.0mg, QW) vs PBO for up to 24wks. in MASH & fibrosis (F1-F3) patients (n=295) with/without type 2 diabetes
- The results depicted, ~83.0% vs 18.2% of patients had improvement in MASH & reached a biopsy-proven improvement in MASH after 48wks. without worsening fibrosis. The 2EP of improving liver fibrosis was also met
- Survodutide is being developed in five P-III studies for obesity incl. (SYNCHRONIZE-1 & SYNCHRONIZE-2), focusing on sub-populations with/without type 2 diabetes, (SYNCHRONIZE-CVOT) for treating cardiovascular disease, CKD or cardiovascular risk factors as well as (SYNCHRONIZE-JP & SYNCHRONIZE-CN) in Japan & China, respectively in specific sub-populations
Ref: Boehringer Ingelheim | Image: Boehringer Ingelheim
Related News:- Boehringer Ingelheim Partners with Sleip AI to Employ AI-technology to Diagnose Lameness in Equines
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
